• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation].[驱动基因突变的非小细胞肺癌免疫治疗研究进展]
Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):201-206. doi: 10.3779/j.issn.1009-3419.2022.102.06.
2
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation 
in Non-small Cell Lung Cancer].[BRAF 突变非小细胞肺癌免疫检查点抑制剂治疗的研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Sep 20;22(9):583-589. doi: 10.3779/j.issn.1009-3419.2019.09.06.
3
[The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].[免疫疗法在不同驱动基因突变的晚期非小细胞肺癌患者中的疗效及预后因素]
Zhonghua Yi Xue Za Zhi. 2022 Apr 5;102(13):922-929. doi: 10.3760/cma.j.cn112137-20211025-02352.
4
[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].一项关于驱动基因阳性且PD-L1高表达的非小细胞肺癌患者病理特征及靶向治疗效果评估的真实世界研究
Zhongguo Fei Ai Za Zhi. 2021 Feb 20;24(2):78-87. doi: 10.3779/j.issn.1009-3419.2021.104.02. Epub 2021 Jan 22.
5
[Analysis of the Efficacy of Immunotherapy on the Posterior Lines 
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].[免疫疗法对晚期表皮生长因子受体（EGFR）突变的非小细胞肺癌患者后线治疗的疗效分析]
Zhongguo Fei Ai Za Zhi. 2021 May 20;24(5):338-344. doi: 10.3779/j.issn.1009-3419.2021.104.06.
6
Targeted Therapy and Immunotherapy for Lung Cancer.肺癌的靶向治疗与免疫治疗
Surg Oncol Clin N Am. 2016 Jul;25(3):601-9. doi: 10.1016/j.soc.2016.02.011.
7
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.携驱动基因突变的肺癌的免疫检查点阻断：择路需明智。
Am Soc Clin Oncol Educ Book. 2020 May;40:372-384. doi: 10.1200/EDBK_280795.
8
[Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer].[BRAF 突变型晚期非小细胞肺癌的靶向治疗与免疫治疗的当前进展]
Zhongguo Fei Ai Za Zhi. 2021 Oct 20;24(10):714-722. doi: 10.3779/j.issn.1009-3419.2021.101.29.
9
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.PD-L1 表达在非小细胞肺癌中的意义：作为预测和预后标志物的锐利双刃剑。
Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.
10
Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.针对携带致癌驱动突变的非小细胞肺癌的 PD-1/PD-L1 轴的当前免疫治疗策略。
Int J Mol Sci. 2021 Dec 27;23(1):245. doi: 10.3390/ijms23010245.

引用本文的文献

1
A Hybrid CNN-Transformer Model for Predicting N Staging and Survival in Non-Small Cell Lung Cancer Patients Based on CT-Scan.基于 CT 扫描的 CNN-Transformer 混合模型预测非小细胞肺癌患者 N 分期和生存情况
Tomography. 2024 Oct 10;10(10):1676-1693. doi: 10.3390/tomography10100123.
2
TGF-β1/miR-30d-5p axis regulating the expression of EMT key factors to induce apoptosis of lung cancer cells.转化生长因子-β1/微小RNA-30d-5p轴调控上皮-间质转化关键因子的表达以诱导肺癌细胞凋亡。
Heliyon. 2024 Sep 14;10(18):e37801. doi: 10.1016/j.heliyon.2024.e37801. eCollection 2024 Sep 30.

本文引用的文献

1
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.特泊替尼联合化疗二线治疗 EGFR 突变晚期 NSCLC 患者：一项多中心 II 期试验。
Signal Transduct Target Ther. 2021 Oct 15;6(1):355. doi: 10.1038/s41392-021-00751-9.
2
Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.研究方案：一项单臂、多中心、Ⅱ期临床试验，评估卡瑞利珠单抗联合阿帕替尼治疗一线免疫治疗后进展的晚期非鳞状 NSCLC。
Thorac Cancer. 2021 Oct;12(20):2825-2828. doi: 10.1111/1759-7714.14113. Epub 2021 Aug 18.
3
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.贝伐珠单抗联合阿替利珠单抗、培美曲塞和卡铂治疗 EGFR 突变型 NSCLC 患者 TKI 治疗失败后的转移性疾病。
Lung Cancer. 2021 Sep;159:18-26. doi: 10.1016/j.lungcan.2021.07.004. Epub 2021 Jul 16.
4
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
5
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs.接受抗PD-1/PD-L1抗体治疗的非小细胞肺癌患者超进展性疾病的免疫特征
Immune Netw. 2020 Dec 21;20(6):e48. doi: 10.4110/in.2020.20.e48. eCollection 2020 Dec.
6
PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China.亚洲人群非小细胞肺癌中PD-L1表达与驱动基因突变的关系：中国1370例病例的大型研究
Ther Adv Med Oncol. 2020 Oct 17;12:1758835920965840. doi: 10.1177/1758835920965840. eCollection 2020.
7
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.免疫疗法和共同突变对KRAS突变型非小细胞肺癌生存的作用。
J Thorac Dis. 2020 Sep;12(9):5086-5095. doi: 10.21037/jtd.2020.04.18.
8
Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗的非小细胞肺癌中 hyperprogressive 疾病的预测模型。
Thorac Cancer. 2020 Oct;11(10):2793-2803. doi: 10.1111/1759-7714.13594. Epub 2020 Aug 11.
9
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.抗 PD-1 抗体在 EGFR 突变和高 PD-L1 表达的 NSCLC 患者中的疗效。
J Cancer Res Clin Oncol. 2021 Jan;147(1):245-251. doi: 10.1007/s00432-020-03329-0. Epub 2020 Jul 23.
10
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.免疫检查点抑制剂在表皮生长因子受体（EGFR）突变的非小细胞肺癌中的应用：从临床到实验室研究
Ther Adv Med Oncol. 2020 Jun 9;12:1758835920930333. doi: 10.1177/1758835920930333. eCollection 2020.

[驱动基因突变的非小细胞肺癌免疫治疗研究进展]

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation].

作者信息

Deng Renfang, Zeng Yue, Pan Yue, Hu Chunhong, Wu Fang

机构信息

Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.

Department of 
Oncology, Zhuzhou Second Hospital, Zhuzhou 412000, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):201-206. doi: 10.3779/j.issn.1009-3419.2022.102.06.

DOI:10.3779/j.issn.1009-3419.2022.102.06
PMID:35340163
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8976200/
Abstract

Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation.
.

摘要

肺癌是全球最致命的恶性肿瘤，非小细胞肺癌（NSCLC）占所有病例的80%。大多数NSCLC患者存在“驱动基因突变”，靶向治疗取得了相对较好的疗效，但部分患者治疗后出现进展或复发。既往研究表明，免疫检查点抑制剂可改善晚期NSCLC的预后并延长生存时间。然而，免疫治疗在具有不同免疫和分子特征的NSCLC患者中的疗效有所不同。免疫治疗在驱动基因突变的NSCLC患者中的疗效存在争议。本综述将总结驱动基因突变的NSCLC患者的免疫特征以及驱动基因突变患者的免疫治疗方向。